Spherix Media
Across the pharma lifecycle, an accurate and complete market view is essential to stay ahead of the curve and uncover emerging healthcare trends.
Despite new market entrants in the form of Gilead’s Livdelzi and Ipsen’s Iqirvo, US gastroenterologists report nearly half of PBC patients suffer from moderate to severe pruritus, underscoring an existing unmet need. Exton, PA, July 17, 2025 – The treatment landscape for primary biliary cholangitis (PBC) has undergone a marked
Research reveals differences in prescribing patterns, treatment goals, and enthusiasm for emerging therapies including Novartis’ Fabhalta and NovelMed’s ruxoprubart, as well as continued use of Alexion’s Soliris and Ultomiris and Apellis’ Empaveli. EXTON, PA, July 17, 2025 – In the latest Special Topix™: Co-Management Approaches in aHUS (US), Spherix Global
The survey shows the evolving landscape of nAMD and DME treatments, highlighting physician preferences, payer influences, and the promise of gene therapy advancements. Spherix Global Insights released data that examine the competitive and complex treatment landscape for neovascular age-related macular degeneration (nAMD) and diabetic macular edema (DME). The Q2 wave
More than 70% of surveyed U.S. ophthalmologists anticipate a fundamentally transformed approach to managing nAMD and DME within the next five years. Exton, PA, July 10, 2025 — Recently released research from Spherix Global Insights provides a timely look at the increasingly competitive and complex treatment landscape for neovascular age-related
New research highlights significant insurance-driven hurdles, increasing second-line uptake of Fabhalta (Novartis), and strong physician interest in pipeline therapies including zaltenibart (Omeros), pozelimab-cemdisiran (Regeneron/Alnylam), and ruxaprubart (NovelMed). EXTON, PA, July 8, 2025 – Paroxysmal nocturnal hemoglobinuria (PNH) is a rare, chronic blood disorder that can affect individuals of any age, race, or
Systemic sclerosis and myositis interstitial lung disease subtypes flagged as most difficult to manage; specialists cite lack of effective treatments and diagnostic clarity EXTON, PA, June 17, 2025 — According to Spherix Global Insights’ newly published Special Topix™: Interstitial Lung Disease in Rheumatology (US) report, both rheumatologists and pulmonologists report
New data released from Spherix Global Insights highlights exciting opportunities in both EU and US for launch brands Hympavzi (Pfizer), Alhemo (Novo Nordisk), Qfitlia (Sanofi) and others, along with emerging gene therapies. EXTON, P.A., June 11, 2025 – As the hemophilia landscape continues to transform, new research from Spherix Global
Findings from Spherix’s fourth annual patient chart audit of more than 500 FSGS patients reveal not only a large unmet need in this market, but also optimism about the future – especially for pipeline agents coming from Travere, Novartis, Vertex, Apellis and Dimerix. EXTON, PA – June 10, 2025 –
Spherix Global Insights’ new patient audit on transfusion-dependent thalassemia reveals strong physician interest in emerging treatments like mitapivat and etavopivat, and provides insight into ideal candidates for curative gene therapies. [Exton, PA, June 04, 2025] – Despite the promise of new curative strategies for beta thalassemia, such as Casgevy (Vertex)
Despite early access friction, Bimzelx’s clinical promise and prescriber satisfaction suggest long-term opportunity in PsA and axSpA. Exton, PA., June 2, 2025 – Just over six months into its dual launch across Psoriatic Arthritis (PsA) and Axial Spondyloarthritis (axSpA), UCB’s Bimzelx (bimekizumab) is demonstrating meaningful promise, though prescriber momentum remains
High rates of biologic naivety, limited switching, and ongoing unmet needs across the gMG landscape create opportunity for brand differentiation. EXTON, Pa, May 15, 2025 — The treatment landscape for generalized myasthenia gravis (gMG) has entered a new era of therapeutic innovation. Since 2022, seven novel targeted biologics have launched,
Following a period of stability in the US biologic asthma market, new data reveals hidden opportunities for differentiation and growing prescriber interest in emerging pipeline therapies Exton, PA, May 13, 2025 – Although no new biologics for asthma have been approved since the 2021 launch of Tezspire (Amgen/AstraZeneca), recent insights
Products such as Tarpeyo (Calliditas), Filspari (Travere) and now Novartis’ Fabhalta and Venrafia provide physicians more options than ever before. Exton, PA, May 8, 2025 – With multiple targeted therapies now available and SGLT2 inhibitors broadly embraced, nephrologists across the globe are redefining how they manage IgA Nephropathy (IgAN) patients.
US hematologists express growing confidence in curative gene therapies such as Casgevy and Lyfgenia, while also showing heightened enthusiasm for next-generation disease-modifying agents. Exton, PA, May 01, 2025 – Patients with sickle cell disease (SCD) continue to face severe complications, despite advances in treatment that have helped mitigate some risks.
The ACR’s updated lupus nephritis treatment guidelines emphasize triple therapy regimens anchored by Benlysta or a calcineurin inhibitor, while Gazyva’s potential role in the evolving landscape remains to be established as the field continues to advance. Exton, PA., April 30, 2025 – The American College of Rheumatology’s (ACR) newly updated
Perceived first-line utility, patient pool expansion, and paradigm-shifting potential distinguish Icotrokinra in the eyes of US dermatologists EXTON, PA, April 14, 2025 – Johnson & Johnson’s recent announcement of positive Phase 3 data for its oral IL-23 receptor antagonist, icotrokinra (JNJ-2113), has sparked notable enthusiasm across the dermatology community. According
Media
04.08.2024
Pfizer’s Velsipity poised to outpace BMS’ Zeposia in ulcerative colitis market, but must head off further competition: analysts
04.08.2024
As Humira biosim sales languish, Boehringer Ingelheim plots layoffs in pivot to hybrid marketing model
04.05.2024
US Gastroenterologists Project Swift Uptake of Madrigal Pharmaceuticals’ Rezdiffra (resmetirom) for the Treatment of…
03.22.2024
Gastroenterologists Slow to Adopt Eli Lilly’s Omvoh, Pfizer’s Velsipity, and Takeda’s subcutaneous formulation of Entyvio for…
